Scientific communications

Featured model - Orthotopic glioblastoma mouse model

01 / 07 / 2020

Our syngeneic glioma mouse model, based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring, represents a suitable tool for chemo- and immunotherapy assessment. It closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration and tumor-induced immunosuppression.

Model responsiveness to standard Temozolomide and immune checkpoint inhibitors i.e. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies, makes it well-suited for testing candidate compounds for their efficacy, as single agents and/or in combination, in promoting anti-tumor activity.

Explicyte is proud to be a certified Nanostring partner - Let’s start the Digital Spatial Profiling revolution together

12 / 08 / 2019

Explicyte is proud to be a certified Nanostring partner -  Let’s start the Digital Spatial Profiling revolution together

To deal with this level of complexity, it’s therefore critical to benefit from technological platform allowing for specific investigation in compartments of interest (eg. tumor vs stroma). Thanks to the GeoMx® platform (Nanostring Inc.), which combines the spatial resolution of immunohistofluorescence with the high-plex gene/protein expression analysis, the Digital Spatial Profiling (DSP) revolution has started.

Combination of in vivo monitoring and flow cytometry-based immunoprofiling on syngeneic tumor models

05 / 24 / 2019

Syngeneic tumor models were becoming invaluable for preclinical development and evaluation of immuno-based therapies in the presence of a functional immunocompetent system. Explicyte is providing a series of syngeneic mouse models including subcutaneous and orthotopic models, which were fully characterized in terms of their responsiveness to immune checkpoint inhibitors (ICI) and their immune infiltration features using a high throughput-compatible flow cytometry platform.